Quantcast
Last updated on April 18, 2014 at 11:01 EDT

Korea in the running to be global leader for Biosimilar by 2020, Finds Frost & Sullivan

January 7, 2013

SINGAPORE, Jan. 7, 2013 /PRNewswire/ — With South Korea introducing a regulatory pathway for manufacturing biologics in 2009, the Government has raised its stakes in the biosimilars market. It is providing both financial and institutional support to help the market emerge as a global leader by 2020. The market is expected to come into its own in 2013-2016, when new products and segments will be launched.

New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Opportunity Analysis for Biosimilars – South Korea, finds that the market earned revenues of $62.3 million in 2011 and estimates this to reach $89.8 million in 2017, with erythropoietin expected to be the biggest revenue generator.

“The South Korean Government considers biosimilars drug development significantly cheaper than new drug development,” saidFrost & Sullivan Research Analyst Poornima Srinivasan. “Moreover, biosimilars’ time-to-market is half of new drugs’, making them attractive investment options.”

However, biosimilars’ requirements of huge upfront investments and infrastructure dissuade potential investors. More importantly, biosimilars need to prove that their clinical efficacy is as robust as biologic innovator drugs’. Currently, physicians and doctors are reluctant to prescribe biosimilars because they may not be as familiar with the biosimilar developer’s capabilities and expertise, as they are with the credentials of innovator drug manufacturing companies.

Further, by 2020, the market will be facing a familiar challenge of dwindling pipeline, as newer and more complex originator molecules need to be identified as target markets. With many domestic companies attempting to establish a foothold, the biosimilars market will also witness changing business models.

High costs associated with biosimilar development will necessitate partnerships with full-service contract research organization (CRO) providers. Aggressive merger and acquisitions encourage more pharmaceuticals to work together to expand their therapeutic products line and bolster their market prospects.

“Growth will be largely fueled fuelled by numerous patent expiries of original biologics between 2011 and 2019,” noted Srinivasan. “The market will also get a boost from the increasing adaptability and ability of large pharmaceutical companies to make the most of opportunities, primarily by focusing on an unique combination of R&D and manufacturing capabilities.”

If you are interested in more information on this research, please send an email to Jessie Loh, Corporate Communications, at jessie.loh@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Opportunity Analysis for Biosimilars – South Korea is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: European Alzheimer’s Disease Medication Market, Contract Research and Manufacturing Services Market in India, 2012 United States Life Sciences Outlook, and United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.


  • The Integrated Value Proposition
    provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

  • The Partnership Infrastructure
    is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on “the next big thing”

Register: Gain access to visionary innovation

Contact:
Donna Jeremiah
Corporate Communications – Asia Pacific
P: +61 (02) 8247 8927
F: +61 (02) 9252 8066
E: djeremiah@frost.com

Jessie Loh
Corporate Communications – Asia Pacific
P: +65 6890 0942
F: +65 6890 0988
E: jessie.loh@frost.com

http://www.frost.com

SOURCE Frost & Sullivan


Source: PR Newswire